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Abstract
Epigenetics connects the divide between genotype and phenotype without
completely altering the genome. Modifications to certain genes can affect cell functions
and produce diseased phenotypes, such as cancer. In some forms of cancer, epigenetic
changes cause the cell to irregularly reproduce, avoid immunological responses, and
operate under unsuitable conditions. This review explores the epigenetic changes that
can occur to produce an oxygen deficient, hypoxically functioning environment that
increases cancer vitality. More specifically, this review will focus on epigenetic alterations
to HIF and p53 genes and briefly cover other genes that can be affected in cancerous cells.
This review found there are multiple reoccurring epigenetic changes that contribute to
the development of cancer, and these changes can be countered by further epigenetic
manipulation. Overall, this review will explain how understanding the epigenetic
changes within cells is extremely beneficial for early diagnosis and, more importantly,
specific treatment of genetic diseases.
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Introduction
Epigenetics is an emerging field that specifically revolves around regulation of gene
expression. These modifications enable a change in phenotype, how genes physically
manifest themselves, by controlling what genes are expressed. Therefore, the DNA
sequence is not permanently altered. Epigenetic control on the genome can be inherited
or environmentally influenced. Additionally, they can have direct or downstream effects.
Downstream effects occur when there is an alteration to the genome that is not
immediately recognized, and products of a pathway may become abnormal. While there
are many forms of epigenetic modifications, DNA methylation and histone modification
are the two most notable epigenetic changes that occur.1 In DNA methylation, a methyl
group may attach to certain cytosine groups in the genome. Cytosine is one of four main
nucleotides of which DNA is composed. When cytosine is present on the genome in
repeating groups, they are referred to as CpG islands.1 The binding of a methyl group to
CpG islands is typically associated with silencing the genes.2 Alternatively, histone
modifications alter the genome by having certain groups bind to histones, the proteins
in which DNA wrap themselves, which affects the rate of transcription.1 These epigenetic
changes can be harmless, such as playing a role in eye color expression, or they can be
devastating and cause diseases, such as cancer.
Cancer is a genetic disease specifically caused by deleterious changes to a cell’s DNA.
Tumors with modifications to HIF and p53 genes occur in high frequency. Typically, the
HIF (Table 1) gene is silenced, otherwise methylated, until it is needed. However, this
71

gene is over-expressed in many cancer cells, meaning it has a high rate of transcription
and, therefore, a more prominent phenotype. This causes the cell to exploit the glycolytic
cycle, effectively trapping the cell and making it essentially immortal as it continues to
endlessly divide.3 Another gene affected in a majority of cancer types is p53.4 Epigenetic
modifications to the p53 (Table 1) gene have been found to be highly correlated to many
forms of cancer because these cells are not self-destructing after becoming cancerous.4
There are several other genes with different functions, including PDGF, ND3, TGF-β1,
PRMT5, as defined in Table 1, that can influence the cancer environment. These
examples show how cancer is caused through several genetic and epigenetic
modifications.
Modifications within the cell’s DNA can cause a cancerous cell to bypass the selfchecking systems that regulate growth and reproduction and cause metastasis by
feeding off normal cells and escaping immune responses. Metastasis is the most
devastating form cancer can take because the cells have begun to invade nearby tissues
by entering the bloodstream or partaking in angiogenesis, the formation of their own
blood vessels. Being able to correlate the epigenetic markers of a changing cell can aid
in the future diagnosis, treatment, and prevention of cancer. This review explores
multiple ways epigenetic changes to the mentioned genes contribute to metastasis via
exploitation of natural cellular mechanisms, such as glycolysis and apoptosis. However,
a problem within the field of epigenetics in relation to disease is the high randomization
of the processes that can cause cancer. This randomization makes it difficult to predict
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when and what changes will occur, leading to increased interest in epigenetic mapping
to diagnosis genetic diseases earlier. This review will explore some of the epigenetic
changes to the cancer genome and emphasize the importance of epigenetic
understanding for cancer treatment.
The Tumor Genome: An Anoxic Environment
Several genetic modifications cause tumor growth and acceleration, particularly
through metabolic shifts within a cell. Epigenetics is profoundly relevant in cancerous
tumors because the tumor environment is so genetically distinct. A large part of the
tumor environment is the fibroblasts associated with them. Tumor fibroblasts are
connective tissue cells that enable the tumor to interact with other noncancerous cells.
These tumor fibroblasts are genetically distinct from normally functioning fibroblasts,
which allows for comparative research to be conducted in order to understand the
modifications at play.5
1. Cancer Associated Fibroblasts
A key feature of the tumor environment are the metabolites associated with
it. Measuring lactate production has become intrinsically important in lab testing to
recognize when a cell has become cancerous. An increase in production indicates a
change within a cell’s metabolism that should not be occurring under proper conditions.6
When the cell does not proceed to aerobic respiration, it recycles cellular materials back
into the glycolytic and pyruvate cycle to produce lactate.6 Results from studies
conducted on cancer associated fibroblasts (CAFs) show that CAFs have nearly double
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the amount of lactate production at every timepoint.7 The overproduction of lactate is
caused by the overexpression of TGFβ-1 and PDGF genes (Table 1) within CAFs trigger
a metabolic switch. This switch revitalizes the glycolytic cycle regardless of oxygen
conditions and allows tumor cells to feed off the byproducts of this cycle, creating cells
that are allowed to thrive in adverse conditions. Overall, different epigenetic
modifications cause the overaction of hypoxia response genes present in CAFs, which
encourages the cell to continue operating anoxically and accelerates the proliferation of
cancerous cells.3
2. Inside A Tumor
While CAFs essentially line a tumor, there are genes within the tumor that are
genetically modified as opposed to healthy cells. One gene directly within the tumor
environment is the gene p53 (Table 1).4 Epigenetic modifications can have downstream
effects to p53 that can contribute to a hyperactive cell, especially when in combination
with mutations to mitochondrial gene ND3 (Table 1). Deletions and overexpression of
ND3 cause a rise in toxic oxygenic radicals, inhibit apoptosis, and contribute to the
recycling of glycolysis.8 Toxic oxygenic radicals are produced when oxygen is not reduced
properly in the oxidative phosphorylation, the process in which ATP is produced. The
inhibition of apoptosis means that the cell will not “self-destruct” if DNA has become
irreparably damaged. This was supported by analyzing cells with overactive ND3 genes
and recognizing downstream effects: high ADP/ATP ratio, increases in glucose
consumption, and increases in lactate production.8 High ADP/ATP ratios and the
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presence of oxygenic radicals indicate that metabolism is not proceeding pass glycolysis
and the pyruvate cycle. Epigenetic overexpression of ND3 also leads to an inhibited p53
apoptotic pathway. While certain studies conducted by Duffy et al didn’t show a direct
correlation to tumor formation, it indicated metabolic changes triggered by genetic
changes, showcasing downstream and direct effects of epigenetic modifications.
Epigenetic Diagnosis and Therapies
1. Genetic Markers
Epigenetics understanding can be used to treat cancer in a multitude of ways. Several
studies are utilizing the knowledge of epigenetic markers to diagnose when cells have
become cancerous. Cheung et al has formatted a system which maps changes in
chromatin through mass cytometry.9 By mapping chromatin changes, researchers can
more easily identify the specific genetic fluctuations that contribute most to cancer
genesis.
2. HIF Therapy
Other ways epigenetics are beneficial is through the treatment of cancer. Specific
research is being conducted to study the effects of epigenetic therapies in the form of
pharmaceuticals. One drug that has shown promise in epigenetic therapy towards cancer
is acriflavine. This drug has been shown to directly bind to HIF genes in tumors, inhibiting
the cell’s capabilities of operating anoxically.10 Furthermore, studies showed that
treatment with acriflavine stunted tumor growth, and in some cases even shrank tumor
size with minimal side effects.10 Acriflavine’s binding acts as an epigenetic modification
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to inhibit HIF within cells and halt hypoxic operations. A different, indirect approach
involves a family of fungal derived HIF1 inhibitors, Epidithiodiketopiperazines (ETPs).
ETPs have shown to inhibit tumor growth via blocking HIF1’s activator binding complex
and thus inhibiting its hypoxic response functions.11 Findings support the viability of
these drugs, as tumor volume was reduced to nearly half of the control group after the
treatment of different ETPs. Another indirect approach to inhibiting HIF has been
studied, as certain drugs have combated the downstream effects of HIF overexpression.
One pharmaceutical compound that has shown potential is isoliquiritigenin, ISL, a
naturally occurring dietary element. When administered in 25 mg/kg and 50 mg/kg
doses, tumor volume was nearly half and a fourth of their original size compared to that
of the control group.12 Supplementally, the body weight of the control group and the
experimental group hardly varied.12 It’s believed that ISL has both direct and
downstream effects towards HIF, as HIF was degraded when in combination with other
inhibitors but was stabilized regardless of ISL presence.12 Overall, these studies show
that understanding the epigenetic modifications within cancer cells is critical for
developing hyperspecialized treatment. Additionally, this shows promise in inhibiting
the gross effects of cancer mutations.
3. Restoration of p53
Not all epigenetic therapies involve the inhibition of a gene. Instead, some drugs
attempt to reverse epigenetic modifications to restore the genome to a more stable
state. One such way this is being done is through the study of berberine, a naturally
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occurring plant compound.13 Berberine’s ability to influence methylation and histone
deacetylation in addition to having minimal cytotoxic affects is an incredible feat in
finding a compound viable for pharmaceutical use.13 Polymerase Chain Reaction (PCR),
a process involving the amplification of a specific gene, enabled a visualization of
berberine’s restoration of p53: the berberine treated group had a significantly darker
mark of p53 has opposed to the control group.13 Restoring p53 enables cells to better selfregulate and destroy themselves should they become cancerous. This study furthermore
supports a need for an understanding of epigenetic modifications, as their potential for
legitimate cancer treatment becomes increasingly evident.
4.Other Therapies
While studies on HIF and p53 are prominent due to their high frequency of mutations
within cancer cells, there are several other ways epigenetic therapies have helped to
evolve cancer treatments. Firstly, researchers are attempting to treat cancer
epigenetically by promoting anti-PD-1 responses in cancer cells.14 Healthy cells have
ligands on their plasma membrane that are recognizable to immune cells and prevent an
inflammatory response. PD-1 is a protein on immune cells that helps them not attack
healthy cells by binding to healthy cell ligands. Cancer cells utilize this mechanism by
having PD-1 binding-ligands and avoiding immunological attacks. Drugs that have
targeted this mechanism by silencing PD-1 hope to expose cancer cells and promote a
better immune response.15 A different approach suggests coupling chemotherapy with
epigenetic modifications in order to preserve the overall health of patients. The
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promotion of PRMT5 and related genes enabled the repair of breaks within the DNA
strand.16 Chemotherapy compromises the strength of the DNA and coupling it with
drugs that preserve this strength show much promise.
Conclusion
Due to the nature of cancer, the study of epigenetics is of extreme value and holds
much promise when trying to understand and treat the disease. There are several ways
that epigenetics can cause cells to become oncogenic. Evidence that verifies the effects
of these modifications are shown through a rise in hypoxic and acidic environments, due
to the cells recycling of glycolysis and producing lactic acid. Coupled changes allow for
tumors to become increasingly potent through evasion of the immune system through
PD-1 binding. Understanding epigenetics is key in treatment of cancer. Observance of
epigenetic markers allow for earlier and more effective treatment. Much research must
still be done to determine what causes these changes and how they can be prevented.
The randomization of epigenetics makes this a difficult task, but a deeper understanding
of how such changes occur could allow for revolutionized treatment of genetic diseases.

78

Table 1. Gene and Drug Abbreviations and their Relation to Cancer
Abbreviation Name

Definition

Relation to
Cancer

HIF3

Hypoxia Induction

Gene that encodes for

Gene is

Factor

the cell’s response to

overexpressed;

hypoxic conditions by

hypomethylated

triggering glycolysis
p538

N/A

Gene that encodes

Gene is silenced;

multiple pathways for

hypermethylated

compromised cell
destruction/apoptosis
PDGF7

Platelet Derived Growth

Aides in cellular growth

Factor

Aid in
transitioning
normal
fibroblasts to
cancerous ones

ND58

NADH Ubiquinone

Mitochondrial gene that

Gene is

Oxidoreductase Subunit

encodes a protein that is

overexpressed;

5

part of complex 1 of

creates excessive

oxidative

oxygen radicals

phosphorylation

and contributes
to the recycling
of glycolysis

TGFβ- 17

Transcription Growth
Factor beta-1

Aides in cellular growth

Aids in
transitioning
normal
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fibroblasts to
cancerous ones
PRMT516

Protein Arginine

Aides in regulating

Overexpressed in

Methyltransferase 5

cellular processes via

many cancers

methylation of target
genes required for cell
division, differentiation,
and growth.
PD-115

Programmed Cell Death

Aides in the

Helps cancer

Inhibitor

immunological response

cells avoid

by ensuring that t-cells

immunological

don’t attack healthy cells

response by
binding to
special receptors
on tumor cells15

ETP11

Epidithiodiketopiperzine Fungal compounds such

Inhibit HIFs by

as chetomin, chaetocin,

blocking their

and gliotoxin

ability to bind
with activators

ISL12

Isoliquiritigenin

A naturally occurring

Can bind directly

compound with various

to cancer-

preventative properties

inducing genes
or block
cancerous
pathways.
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